Related Experiment Video
Updated: Jun 6, 2026

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
Published on: January 22, 2021
Antimicrobial disposition in pulmonary epithelial lining fluid of horses, part III. cefquinome
L Winther1, K E Baptiste, C Friis
1Faculty of Life Sciences, Department of Large Animal Sciences, University of Copenhagen, Copenhagen, Denmark. low@dkma.dk
Abstract:
Cefquinome concentrations, following intravenous and aerosol administration to horses, in pulmonary epithelial lining fluid (PELF) were examined and compared to plasma concentrations. Single dose of cefquinome sulphate (1 mg/kg) was administered intravenously to six horses followed by a single aerosol administration (225 mg) with a wash-out period of 14 days between treatments. After each drug administration, cefquinome concentrations in plasma and PELF, obtained by intrabronchial cotton swabs, were determined. After intravenous administration, cefquinome concentrations in plasma declined fast and were not detectable after 12 h. After aerosol administration, plasma concentrations were low or below limit of quantification (LOQ) during the entire sampling period. The degree of penetration of cefquinome into PELF after intravenous administration as described by the AUC(PELF) /AUC(plasma) ratio was 0.33. Following aerosol administration, cefquinome concentrations in PELF were high, but only detectable for 4 h. Based on AUC values, total cefquinome concentrations in PELF were one-third of total plasma concentrations after intravenous administration together with shorter time above Minimum Inhibitory Concentrations (T > MIC) in PELF, thus twice daily dosing may be required when treating lower airway infections in horses. Lower doses of cefquinome can be administered as aerosols providing high local drug concentrations in lung, but additional optimization of formulation is needed to improve distribution and persistence in lung.
More Related Videos
07:50Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Clinical Significance of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Antimicrobial Effectiveness
Mechanism of Antibiotic Resistance in MRSA